<?xml version="1.0" encoding="UTF-8" standalone="yes"?><dealRecordsOutput><serviceExecutionTime>288</serviceExecutionTime><Deal id="107149"><Title>Vanda and Novartis agreement for iloperidone (Fanapt) for schizophrenia and related disorders  </Title><CompanyPrincipal id="23137">Novartis AG</CompanyPrincipal><CompanyPartner id="1008598">Vanda Pharmaceuticals Inc</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="18.4" min="18.4"/><ValueProjected accuracy="&gt;" max="197.0" min="197.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="=" max="204.5" min="204.5"/><ValueProjected accuracy="&gt;" max="500.4" min="235.4"/></ValuesToPartner><TerritoriesIncluded><Territory id="IL">Israel</Territory><Territory id="WO">World</Territory></TerritoriesIncluded><TerritoriesExcluded><Territory id="CA">Canada</Territory><Territory id="US">US</Territory></TerritoriesExcluded><PaymentsProjected><PaymentsToPartner><Payment><Reference>1049123</Reference><Type>Other Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="265.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1049123</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="200.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1622575</Reference><Type>Other Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="25.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1382630</Reference><Type>Royalty Payment</Type><Value accuracy="&gt;="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="10.4" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q4">0.0</ReportedAmountMil></Value></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference>1395912</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1622690</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>543641</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="0.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2014 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2050936</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2004 Q1">16.0</ReportedAmountMil></Value></Payment><Payment><Reference>2050901</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="17.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2050936</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2004 Q1">16.0</ReportedAmountMil></Value></Payment><Payment><Reference>1032727</Reference><Type>Other Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="12.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2050901</Reference><Type>Sales Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="75.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2050901</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="17.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2050936</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2006 Q1">16.0</ReportedAmountMil></Value></Payment><Payment><Reference>2050936</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="0.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>2050901</Reference><Type>Sales Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="75.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2004 Q1">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="299">Schizophrenia</Indication></Indications><ActionsPrimary><Action id="585">5-HT 2a receptor antagonist</Action><Action id="16396">Nicotinic ACh receptor alpha 7 subunit stimulator</Action><Action id="150">Dopamine D2 receptor antagonist</Action><Action id="148">Dopamine D1 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2941">Antidepressant</Action><Action id="2943">Antipsychotic</Action><Action id="284">Nootropic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology><Technology id="660">Oral sustained release formulation</Technology><Technology id="589">Sustained release formulation</Technology></Technologies><DateStart>2004-06-04T00:00:00Z</DateStart><DateEventMostRecent>2014-12-31T00:00:00Z</DateEventMostRecent><Drugs><Drug id="57444"><DrugNameDisplay>VQW-765</DrugNameDisplay><PhaseHighestStart id="C1">Phase 1 Clinical</PhaseHighestStart><PhaseHighestNow id="C2">Phase 2 Clinical</PhaseHighestNow></Drug><Drug id="10106"><DrugNameDisplay>iloperidone</DrugNameDisplay><PhaseHighestStart id="C3">Phase 3 Clinical</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug><Drug id="54753"><DrugNameDisplay>iloperidone depot (schizophrenia), Vanda/Novartis</DrugNameDisplay><PhaseHighestStart id="C2">Phase 2 Clinical</PhaseHighestStart><PhaseHighestNow id="C2">Phase 2 Clinical</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In June 2004,  &lt;ulink linkType="Company" linkID="23137"&gt;Novartis&lt;/ulink&gt; licensed to &lt;ulink linkType="Company" linkID="1008598"&gt;Vanda Pharmaceuticals&lt;/ulink&gt; worldwide rights to develop and commercialize &lt;ulink linkType="Drug" linkID="10106"&gt;iloperidone&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="54753"&gt;depot iloperidone&lt;/ulink&gt; for the treatment of schizophrenia and related disorders [&lt;ulink linkType="Reference" linkID="543641"&gt;543641&lt;/ulink&gt;], [ [&lt;ulink linkType="Reference" linkID="2050901"&gt;2050901&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2050936"&gt;2050936&lt;/ulink&gt;]. In May 2009, a milestone was achieved [&lt;ulink linkType="Reference" linkID="1032727"&gt;1032727&lt;/ulink&gt;]. In October 2009, the agreement was restructured as &lt;ulink linkType="Company" linkID="25599"&gt;Novartis Pharma&lt;/ulink&gt; (a subsidiary of Novartis) relicensed US and Canadian rights [&lt;ulink linkType="Reference" linkID="1049123"&gt;1049123&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049124"&gt;1049124&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049262"&gt;1049262&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1835839"&gt;1835839&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2050936"&gt;2050936&lt;/ulink&gt;]. By the end of 2009, Novartis had received the remaining milestone payment triggered by the May 2009 drug approval [&lt;ulink linkType="Reference" linkID="1075414"&gt;1075414&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1032727"&gt;1032727&lt;/ulink&gt;]. In 2011 Vanda received royalties from Novartis [&lt;ulink linkType="Reference" linkID="1382630"&gt;1382630&lt;/ulink&gt;].  In August 2012, Vanda received market approval for the commercialization of Fanapt in Israel [&lt;ulink linkType="Reference" linkID="2005761"&gt;2005761&lt;/ulink&gt;]. In October 2012, Novartis  entered into  an option not to co-commercialize Fanapt in  Europe and certain other countries including, Switzerland, Norway, Liechtenstein and Iceland [&lt;ulink linkType="Reference" linkID="1395912"&gt;1395912&lt;/ulink&gt;]. In 2012, Vanda received royalties from Novartis [&lt;ulink linkType="Reference" linkID="1382630"&gt;1382630&lt;/ulink&gt;]. In October 2013, Vanda received market approval for the commercialization of Fanapt in Mexico [&lt;ulink linkType="Reference" linkID="2005761"&gt;2005761&lt;/ulink&gt;]. By December 2014, Vanda no longer had an active distributor relationship in Mexico [&lt;ulink linkType="Reference" linkID="2005761"&gt;2005761&lt;/ulink&gt;]. In December 2014,  Vanda  reached a settlement agreement to regain US and Canadian rights for Novartis' Fanapt and would also acquire exclusive worldwide license to develop and commercialize &lt;ulink linkType="Drug" linkID="57444"&gt;AQW-051&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1622575"&gt;1622575&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1622690"&gt;1622690&lt;/ulink&gt;].  &lt;/para&gt;</Summary><TimeLine><Event><Date>2012-08-31T00:00:00Z</Date><Drugs><DrugLink id="10106" nameDisplay="iloperidone"/><DrugLink id="54753" nameDisplay="iloperidone depot (schizophrenia), Vanda/Novartis"/><DrugLink id="57444" nameDisplay="VQW-765"/></Drugs><Summary>&lt;para&gt;- In August 2012, Vanda received market approval for the commercialization of Fanapt in Israel [&lt;ulink linkType="Reference" linkID="2005761"&gt;2005761&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2013-10-31T00:00:00Z</Date><Drugs><DrugLink id="10106" nameDisplay="iloperidone"/><DrugLink id="54753" nameDisplay="iloperidone depot (schizophrenia), Vanda/Novartis"/><DrugLink id="57444" nameDisplay="VQW-765"/></Drugs><Summary>&lt;para&gt;- In October 2013, Vanda received market approval for the commercialization of Fanapt in Mexico [&lt;ulink linkType="Reference" linkID="2005761"&gt;2005761&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2014-12-31T00:00:00Z</Date><Drugs><DrugLink id="10106" nameDisplay="iloperidone"/><DrugLink id="54753" nameDisplay="iloperidone depot (schizophrenia), Vanda/Novartis"/><DrugLink id="57444" nameDisplay="VQW-765"/></Drugs><Summary>&lt;para&gt;- By December 2014, Vanda no longer had an active distributor relationship in Mexico [&lt;ulink linkType="Reference" linkID="2005761"&gt;2005761&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2004-06-04T00:00:00Z</Date><Drugs><DrugLink id="10106" nameDisplay="iloperidone"/><DrugLink id="54753" nameDisplay="iloperidone depot (schizophrenia), Vanda/Novartis"/></Drugs><PaymentsToPrincipal><Payment><Reference id="2050901">2050901</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2004 Q1" exchangeRateUS="1">0.5</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="C2">Phase 2 Clinical</Stage><Summary>&lt;para&gt;- In June 2004,  &lt;ulink linkType="Company" linkID="23137"&gt;Novartis&lt;/ulink&gt; licensed to &lt;ulink linkType="Company" linkID="1008598"&gt;Vanda Pharmaceuticals&lt;/ulink&gt; worldwide rights to develop and commercialize &lt;ulink linkType="Drug" linkID="10106"&gt;iloperidone&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="54753"&gt;depot iloperidone&lt;/ulink&gt; for the treatment of schizophrenia and related disorders. &lt;/para&gt;&lt;para&gt;- Vanda would complete phase III development of iloperidone and assume responsibility for product registration. &lt;/para&gt;&lt;para&gt;-  Novartis would receive $0.5 million in cash within 10 days and  would also receive $17 million in development milestone payments of which $5 million would receive for the first development milestone upon the first NDA filing and $12 million as second development milestones upon final marketing authorization approval in US.&lt;/para&gt;&lt;para&gt;- Novartis would also receives $75 million in sales milestones of which $25 million upon net sale of $250 million, $25 million if sales exceed $25 million and $25 million if the net sales exceeds $250 million for four consecutive quater period.&lt;/para&gt;&lt;para&gt; - Novartis would receive 25% royalties for annual net sales if the product in non-patent countries for five years&lt;/para&gt;&lt;para&gt;- Vanda would pay $1 million milestone payment upon the initiation of the phase II clinical trial, should Vanda's aggregate expenditure on preclinical and phase I work not reach $2 million. &lt;/para&gt;&lt;para&gt;- If upon the initiation of the first qualified phase II clinical trial, Vanda's cost of preclinical and phase I work exceeds $2 million and is less than $3 million. &lt;/para&gt;&lt;para&gt;- Vanda would pay a milestone payment equal to $3 million minus the cost of preclinical and phase I work. For Scenario I milestone payment, Vanda would pay $5 million for first acceptance for a product, $10 million for the receipt of regulatory approval for a product in a major market country. &lt;/para&gt;&lt;para&gt;- For Scenario II milestone payment, Vanda would pay $1 million for Novartis selection of the Scenario II option. &lt;/para&gt;&lt;para&gt;- Vanda would pay $3 million for first NDA acceptance for a product, $5 million for the receipt of regulatory approval for a product in a major market country. &lt;/para&gt;&lt;para&gt;- $10 million for the first $250 million in cumulative net sales of products. For Scenario III milestone payment, Vanda would pay $25 million for first NDA acceptance for a product, $30 million for the receipt of regulatory approval for a product in a major market country. $10 million for the first $250 million in cumulative net sales of products.&lt;/para&gt;&lt;para&gt;-  If Novartis does not exercise its scenario II or scenario III, would  pay 16% royalty.&lt;/para&gt;&lt;para&gt;-  If Novartis exercises its scenario II option, would pay 10% royalty. &lt;/para&gt;&lt;para&gt;- If Novartis exercises its scenario III option, would pay 15% royalty  on annual net sales of the product [&lt;ulink linkType="Reference" linkID="543641"&gt;543641&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1646155"&gt;1646155&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2050901"&gt;2050901&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2050936"&gt;2050936&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2009-05-07T00:00:00Z</Date><Drugs><DrugLink id="10106" nameDisplay="iloperidone"/><DrugLink id="54753" nameDisplay="iloperidone depot (schizophrenia), Vanda/Novartis"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1032727">1032727</Reference><Type>Other Milestones</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2009 Q1" exchangeRateUS="1">7</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;- In May 2009,  Fanapt (iloperidone) was approved, Vanda would pay Novartis a $12 million milestone payment, $7 million was paid and the remaining $5 million was due in November 2009 [&lt;ulink linkType="Reference" linkID="1032727"&gt;1032727&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Regulatory Milestone</Type></Event><Event><Date>2009-10-12T00:00:00Z</Date><Drugs><DrugLink id="10106" nameDisplay="iloperidone"/><DrugLink id="54753" nameDisplay="iloperidone depot (schizophrenia), Vanda/Novartis"/></Drugs><Summary>&lt;para&gt;- In October 2009, the deal was amended, with &lt;ulink linkType="Company" linkID="25599"&gt;Novartis Pharma&lt;/ulink&gt; (a subsidiary of Novartis) relicensing US and Canadian development and commercialization rights to both iloperidone and depot iloperidone for schizophrenia from Vanda Pharmaceuticals.&lt;/para&gt;&lt;para&gt;-  At that time, the amendment was still subject to approval and customary regulatory closing conditions, expected by the end of 2009. &lt;/para&gt;&lt;para&gt;- If approved, Novartis would pay  $200 million upfront to Vanda, up to $265 million in milestone payments, plus royalties based on the commercialization of  iloperidone in the US and Canada. Vanda retained rights outside of these territories; &lt;/para&gt;&lt;para&gt;- however, Novartis Pharma  was granted an option for either co-commercialization outside of the US and Canada, or receive a royalty on sales. As part of the original sublicense agreement, licensor to Novartis &lt;ulink linkType="Company" linkID="20377"&gt;Titan  Pharmaceuticals&lt;/ulink&gt; would be eligible to receive  royalties of 8% of net sales of iloperidone up to  $200 million, and 10% on sales above $200 million. Restructured agreement worth $465 million. &lt;/para&gt;&lt;para&gt;- Vanda would pay an upfront fee of $0.5 million. Vanda would pay an first development milestone payment of $5 million upon first NDA filing in the US. &lt;/para&gt;&lt;para&gt;- A second milestone payment of $12 million would pay upon the marketing approval in the US.&lt;/para&gt;&lt;para&gt;- 25% royalties on net sales of the product and sublicense in the ROW territory.15% on royalties on net sales of the depot formulation of product .&lt;/para&gt;&lt;para&gt;- An one-time non-refundable upfront fee of $200 million within thirty day after receipt by Novartis. A development milestone payment of $40 million would pay within 60days for the receipt of the first NDA in the US for the depot formulation of the product. [&lt;ulink linkType="Reference" linkID="1049123"&gt;1049123&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049124"&gt;1049124&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049262"&gt;1049262&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1646155"&gt;1646155&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2050936"&gt;2050936&lt;/ulink&gt;]&lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2009-12-01T00:00:00Z</Date><Drugs><DrugLink id="10106" nameDisplay="iloperidone"/><DrugLink id="54753" nameDisplay="iloperidone depot (schizophrenia), Vanda/Novartis"/></Drugs><PaymentsToPartner><Payment><Reference id="1061218">1061218</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2009 Q3" exchangeRateUS="1">200</USDAmountMil></Value></Payment></PaymentsToPartner><Summary>&lt;para&gt;- In December 2009, the Hart-Scott-Rodino approval waiting period expired, the amended transaction was approved and Novartis Pharma gained US and Canadian rights to the drugs. &lt;/para&gt;&lt;para&gt;- A $200 million payment was made to Vanda from Novartis Pharma. &lt;/para&gt;&lt;para&gt;- Novartis Pharma would continue with development and commercialization efforts for both programs, while Vanda retained rights outside of these territories. &lt;/para&gt;&lt;para&gt;- Novartis Pharma was granted an option to co-commercialize outside of the US and Canada [&lt;ulink linkType="Reference" linkID="1061218"&gt;1061218&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2009-12-31T00:00:00Z</Date><Drugs><DrugLink id="10106" nameDisplay="iloperidone"/><DrugLink id="54753" nameDisplay="iloperidone depot (schizophrenia), Vanda/Novartis"/><DrugLink id="57444" nameDisplay="VQW-765"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1075414">1075414</Reference><Type>Other Milestones</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2009 Q3" exchangeRateUS="1">5</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;- By the end of 2009, Novartis had received the remaining $5 million milestone payment triggered by the May 2009 approval of Fanapt [&lt;ulink linkType="Reference" linkID="1075414"&gt;1075414&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1032727"&gt;1032727&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Regulatory Milestone</Type></Event><Event><Date>2011-12-31T00:00:00Z</Date><Drugs><DrugLink id="10106" nameDisplay="iloperidone"/><DrugLink id="54753" nameDisplay="iloperidone depot (schizophrenia), Vanda/Novartis"/><DrugLink id="57444" nameDisplay="VQW-765"/></Drugs><PaymentsToPartner><Payment><Reference id="1382630">1382630</Reference><Type>Royalty Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2011 Q3" exchangeRateUS="1">4.5</USDAmountMil></Value></Payment></PaymentsToPartner><Summary>&lt;para&gt;- In 2011 Vanda received royalties of $4.5 million  [&lt;ulink linkType="Reference" linkID="1382630"&gt;1382630&lt;/ulink&gt;]. &lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2012-10-31T00:00:00Z</Date><Drugs><DrugLink id="10106" nameDisplay="iloperidone"/><DrugLink id="54753" nameDisplay="iloperidone depot (schizophrenia), Vanda/Novartis"/><DrugLink id="57444" nameDisplay="VQW-765"/></Drugs><Summary>&lt;para&gt;- In October 2012, Novartis  entered into  an option not to co-commercialize Fanapt in  Europe and certain other countries including, Switzerland, Norway, Liechtenstein and Iceland and  would also receive royalty payments on net sales in those countries [&lt;ulink linkType="Reference" linkID="1395912"&gt;1395912&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2012-12-31T00:00:00Z</Date><Drugs><DrugLink id="10106" nameDisplay="iloperidone"/><DrugLink id="54753" nameDisplay="iloperidone depot (schizophrenia), Vanda/Novartis"/><DrugLink id="57444" nameDisplay="VQW-765"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1382630">1382630</Reference><Type>Royalty Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2012 Q3" exchangeRateUS="1">5.9</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;- In 2012, Vanda received royalties of $5.9 million  [&lt;ulink linkType="Reference" linkID="1382630"&gt;1382630&lt;/ulink&gt;]. &lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2014-12-22T00:00:00Z</Date><Drugs><DrugLink id="10106" nameDisplay="iloperidone"/><DrugLink id="54753" nameDisplay="iloperidone depot (schizophrenia), Vanda/Novartis"/><DrugLink id="57444" nameDisplay="VQW-765"/></Drugs><Summary>&lt;para&gt;- In December 2014,  Vanda Pharmaceuticals reached a settlement agreement to regain US and Canadian rights for Novartis' Fanapt. Novartis would make a $25 million equity investment in Vanda at $13.82/share. Vanda would also acquire exclusive worldwide license to develop and commercialize &lt;ulink linkType="Drug" linkID="57444"&gt;AQW-051&lt;/ulink&gt;. Vanda would be responsible for all development costs for AQW-051. Novartis would be eligible for tiered-royalties upon net sales at percentage rates up to the mid-teens [&lt;ulink linkType="Reference" linkID="1622575"&gt;1622575&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1622690"&gt;1622690&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event></TimeLine><IsOptional>Y</IsOptional><CrossReferences><SourceEntity id="57444" type="Drug"><TargetEntity id="441155" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="10106" type="Drug"><TargetEntity id="165804" type="siDrug">Iloperidone</TargetEntity></SourceEntity><SourceEntity id="1008598" type="Company"><TargetEntity id="4295899966" type="organizationId">Vanda Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"/><TargetEntity id="10039626" type="MEDDRA"/><TargetEntity id="D012559" type="MeSH"/><TargetEntity id="-729613619" type="omicsDisease"/><TargetEntity id="65" type="siCondition"/></SourceEntity><SourceEntity id="585" type="Action"><TargetEntity id="210" type="Mechanism">5-HT2A Antagonists</TargetEntity></SourceEntity><SourceEntity id="148" type="Action"><TargetEntity id="124" type="Mechanism">Dopamine D1 Antagonists</TargetEntity></SourceEntity><SourceEntity id="150" type="Action"><TargetEntity id="125" type="Mechanism">Dopamine D2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="16396" type="Action"><TargetEntity id="1332" type="Mechanism">Nicotinic alpha7 Agonists</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="119806"><Title>BMS to collaborate with 3DP on therapeutics for gene-based targets </Title><CompanyPrincipal id="21960">3-Dimensional Pharmaceuticals Inc</CompanyPrincipal><CompanyPartner id="15065">Bristol-Myers Squibb Co</CompanyPartner><Type>Drug - Discovery/Design</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="23.5" min="23.5"/><ValueProjected accuracy="&gt;" max="102.8" min="102.8"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="=" max="4.5" min="4.5"/><ValueProjected accuracy="=" max="4.5" min="4.5"/></ValuesToPartner><PaymentsProjected><PaymentsToPartner><Payment><Reference>394256</Reference><Type>Other</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="4.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2000 Q3">0.0</ReportedAmountMil></Value></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="22.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2000 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>374119</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="22.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2000 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="14.4" usdExchangeRate="1.0" usdExchangeRatePeriod="2000 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>374119</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="15.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2000 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="15.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2000 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2000 Q2">7.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="14.4" usdExchangeRate="1.0" usdExchangeRatePeriod="2000 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2000 Q2">7.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="746">Infectious disease</Indication><Indication id="40">Bacterial infection</Indication><Indication id="344">Viral infection</Indication></Indications><Technologies><Technology id="547">Protein folding</Technology><Technology id="1024">Unspecified gene technology</Technology></Technologies><DateStart>2000-07-11T00:00:00Z</DateStart><DateEventMostRecent>2000-12-18T00:00:00Z</DateEventMostRecent><Summary>&lt;para&gt;In July 2000, &lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS) and &lt;ulink linkType="Company" linkID="21960"&gt;3-Dimensional Pharmaceuticals&lt;/ulink&gt; (3DP)  formed a drug discovery alliance for the R&amp;amp;D of small-molecule pharmaceuticals directed to gene-based biological targets identified by BMS [&lt;ulink linkType="Reference" linkID="374119"&gt;374119&lt;/ulink&gt;]. In December 2000, the deal was amended [&lt;ulink linkType="Reference" linkID="394256"&gt;394256&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2000-07-11T00:00:00Z</Date><Drugs/><PaymentsToPrincipal><Payment><Reference id="374119">374119</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2000 Q2" exchangeRateUS="1">23.5</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="DR">Discovery</Stage><Summary>&lt;para&gt;In July 2000, &lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS) and &lt;ulink linkType="Company" linkID="21960"&gt;3-Dimensional Pharmaceuticals&lt;/ulink&gt; (3DP)  formed a drug discovery alliance for the R&amp;amp;D of small-molecule pharmaceuticals directed to gene-based biological targets identified by BMS. 3DP received upfront licensing and technology access fees of $23.5 million, and would receive committed research funding of $14.4 million over the first three years of the collaboration. 3DP would also be eligible to receive milestone payments and royalties on sales of resulting products. BMS was to receive exclusive worldwide rights to compounds discovered or developed through the collaboration, and non-exclusive licenses for certain patented applications involving 3DP's DirectedDiversity combinatorial chemistry and chemi-informatics, ThermoFluor high throughput screening and Protein Expression/Refolding technology [&lt;ulink linkType="Reference" linkID="374119"&gt;374119&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2000-12-18T00:00:00Z</Date><Drugs/><PaymentsToPartner><Payment><Reference id="394256">394256</Reference><Type>Other</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2000 Q3" exchangeRateUS="1">4.5</USDAmountMil></Value></Payment></PaymentsToPartner><Summary>&lt;para&gt;In December 2000, the agreement was amended to reflect an increase in &lt;ulink linkType="Company" linkID="15065"&gt;BMS&lt;/ulink&gt;'s commitment to purchase ThermoFluor high throughput screening workstations from three to seven, and removal of non-exclusive licenses to &lt;ulink linkType="Company" linkID="21960"&gt;3DP&lt;/ulink&gt;'s protein expression/refolding technology and 3DP's planned GPCR structural genomics database. This resulted in the return of $4.5 million to BMS of the $23.5 million in upfront fees [&lt;ulink linkType="Reference" linkID="394256"&gt;394256&lt;/ulink&gt;]. &lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event></TimeLine><Patents><Patent id="IN2793715"><Number>US-05463564</Number><Title>System and method of automatically generating chemical compounds with desired properties.</Title></Patent></Patents><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="21960" type="Company"><TargetEntity id="4295900457" type="organizationId">3 Dimensional Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="344" type="ciIndication"><TargetEntity id="10047461" type="MEDDRA"/><TargetEntity id="D014777" type="MeSH"/><TargetEntity id="-1748727144" type="omicsDisease"/><TargetEntity id="854" type="siCondition"/></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"/><TargetEntity id="10060945" type="MEDDRA"/><TargetEntity id="D001424" type="MeSH"/><TargetEntity id="-1693440076" type="omicsDisease"/><TargetEntity id="800" type="siCondition"/></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"/><TargetEntity id="D007239" type="MeSH"/><TargetEntity id="-367065996" type="omicsDisease"/><TargetEntity id="799" type="siCondition"/></SourceEntity></CrossReferences></Deal><Deal id="120534"><Title>Eli Lilly and Amylin to codevelop exenatide worldwide    </Title><CompanyPrincipal id="14216">Amylin Pharmaceuticals Inc</CompanyPrincipal><CompanyPartner id="17810">Eli Lilly &amp; Co</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="145.0" min="145.0"/><ValueProjected accuracy="=" max="870.0" min="870.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="=" max="1259.0" min="1259.0"/><ValueProjected accuracy="&gt;" max="1659.0" min="1659.0"/></ValuesToPartner><TerritoriesIncluded><Territory id="WO">World</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPartner><Payment><Reference>1237315</Reference><Type>Other Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="150.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2011 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1237315</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="250.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2011 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1237315</Reference><Type>Other</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1314371</Reference><Type>Other</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1259.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q2">0.0</ReportedAmountMil></Value></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference>464704</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="80.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2002 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>464704</Reference><Type>Loan/Credit</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="110.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2002 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>464704</Reference><Type>Profit Split(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2002 Q2">50.0</ReportedAmountMil></Value></Payment><Payment><Reference>464704</Reference><Type>Other Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="215.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2002 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>464704</Reference><Type>Upfront Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="30.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2002 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>464704</Reference><Type>Other Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="215.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2002 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>464704</Reference><Type>Upfront Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="30.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2002 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>464704</Reference><Type>Profit Split(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2002 Q2">50.0</ReportedAmountMil></Value></Payment><Payment><Reference>464704</Reference><Type>Loan/Credit</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="110.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2002 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>464704</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="80.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2002 Q2">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><ActionsSecondary><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="80">Peptide</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><DateStart>2002-09-19T00:00:00Z</DateStart><DateEnd>2011-11-08T00:00:00Z</DateEnd><DateEventMostRecent>2012-08-09T00:00:00Z</DateEventMostRecent><Drugs><Drug id="13572"><DrugNameDisplay>exenatide</DrugNameDisplay><PhaseHighestStart id="C3">Phase 3 Clinical</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug><Drug id="15534"><DrugNameDisplay>exenatide (controlled-release, Medisorb), AstraZeneca</DrugNameDisplay><PhaseHighestStart id="C2">Phase 2 Clinical</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug><Drug id="71833"><DrugNameDisplay>exenatide (microsphere suspension formulation, type 2 diabetes), Astrazeneca</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In September 2002, &lt;ulink linkType="Company" linkID="17810"&gt;Eli Lilly&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="14216"&gt;Amylin Pharmaceuticals&lt;/ulink&gt; signed a global agreement to collaborate on the development and commercialization of  &lt;ulink linkType="Drug" linkID="13572"&gt;exenatide&lt;/ulink&gt; (Byetta) for the potential treatment for type II diabetes [&lt;ulink linkType="Reference" linkID="464704"&gt;464704&lt;/ulink&gt;].  In October 2006, the agreement was amended [&lt;ulink linkType="Reference" linkID="2056195"&gt;2056195&lt;/ulink&gt;]. In May 2008, the parties amended the US copromotion agreement [&lt;ulink linkType="Reference" linkID="2056204"&gt;2056204&lt;/ulink&gt;]. In October 2008, The parties entered a supply agreement, pursuant to which Amylin will receive upfront an line of credit (see separate transaction) [&lt;ulink linkType="Reference" linkID="1836322"&gt;1836322&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2056208"&gt;2056208&lt;/ulink&gt;]. In May 2009, the parties entered into a cost allocation agreement. Lilly would pay 50% and Amylin would pay 50% of development and commercialization costs in the US,  Lilly  would  pay 100% of the development and commercialization costs outside the US, Lilly would pay 53% of global costs and Amylin would pay 47% of global costs. The outside US royalties  were amended from 12% to 10% and 19% to 16% [&lt;ulink linkType="Reference" linkID="2056225"&gt;2056225&lt;/ulink&gt;]. By December 2010, Amylin had earned a milestone related to launch of exenatide in Japan [&lt;ulink linkType="Reference" linkID="1166200"&gt;1166200&lt;/ulink&gt;]. In November 2011, the companies agreed to end their  collaboration  for exenatide and  controlled-release formulation &lt;ulink linkType="Drug" linkID="15534"&gt;Bydureon&lt;/ulink&gt; in order to resolve the outstanding litigation between them. Lilly would return worldwide rights back to Amylin, beginning in the US on November 30, 2011[&lt;ulink linkType="Reference" linkID="1237315"&gt;1237315&lt;/ulink&gt;].  In August 2012, following its acquisition by &lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb&lt;/ulink&gt;, Amylin  made a revenue sharing obligation payment   to Lilly with respect to exenatide  [&lt;ulink linkType="Reference" linkID="1314371"&gt;1314371&lt;/ulink&gt;]. &lt;/para&gt;</Summary><TimeLine><Event><Date>2008-10-31T00:00:00Z</Date><Drugs><DrugLink id="13572" nameDisplay="exenatide"/><DrugLink id="15534" nameDisplay="exenatide (controlled-release, Medisorb), AstraZeneca"/><DrugLink id="71833" nameDisplay="exenatide (microsphere suspension formulation, type 2 diabetes), Astrazeneca"/></Drugs><Summary>&lt;para&gt;- In October 2008, The parties entered a supply agreement, pursuant to which Amylin will receive $125M up front and a $165M line of credit (see separate transaction) [&lt;ulink linkType="Reference" linkID="1836322"&gt;1836322&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2056208"&gt;2056208&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2006-10-31T00:00:00Z</Date><Drugs><DrugLink id="13572" nameDisplay="exenatide"/><DrugLink id="15534" nameDisplay="exenatide (controlled-release, Medisorb), AstraZeneca"/><DrugLink id="71833" nameDisplay="exenatide (microsphere suspension formulation, type 2 diabetes), Astrazeneca"/></Drugs><Summary>&lt;para&gt;- In October 2006, the agreement was amended [&lt;ulink linkType="Reference" linkID="2056195"&gt;2056195&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2008-05-08T00:00:00Z</Date><Drugs><DrugLink id="13572" nameDisplay="exenatide"/><DrugLink id="15534" nameDisplay="exenatide (controlled-release, Medisorb), AstraZeneca"/><DrugLink id="71833" nameDisplay="exenatide (microsphere suspension formulation, type 2 diabetes), Astrazeneca"/></Drugs><Summary>&lt;para&gt;- In May 2008, the parties amended the US copromotion agreement [&lt;ulink linkType="Reference" linkID="2056204"&gt;2056204&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2009-05-04T00:00:00Z</Date><Drugs><DrugLink id="13572" nameDisplay="exenatide"/><DrugLink id="15534" nameDisplay="exenatide (controlled-release, Medisorb), AstraZeneca"/><DrugLink id="71833" nameDisplay="exenatide (microsphere suspension formulation, type 2 diabetes), Astrazeneca"/></Drugs><Summary>&lt;para&gt;- In May 2009, the parties entered into a cost allocation agreement. Lilly would pay 50% and Amylin would pay 50% of development and commercialization costs in the US,  Lilly  would  pay 100% of the development and commercialization costs outside the US, Lilly would pay 53% of global costs and Amylin would pay 47% of global costs.&lt;/para&gt;&lt;para&gt;- The outside US royalties  were amended from 12% to 10% and 19% to 16% [&lt;ulink linkType="Reference" linkID="2056225"&gt;2056225&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2002-09-19T00:00:00Z</Date><Drugs><DrugLink id="13572" nameDisplay="exenatide"/></Drugs><PaymentsToPrincipal><Payment><Reference id="464704">464704</Reference><Type>Other</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2002 Q2" exchangeRateUS="1">80</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="C3">Phase 3 Clinical</Stage><Summary>&lt;para&gt;In September 2002, &lt;ulink linkType="Company" linkID="17810"&gt;Eli Lilly&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="14216"&gt;Amylin Pharmaceuticals&lt;/ulink&gt; signed a global agreement to collaborate on the development and commercialization of  exenatide for the potential treatment for type II diabetes. Lilly was to make initial nonrefundable payments to Amylin of $80 million and to purchase $30 million of Amylin common stock. Lilly was also to pay Amylin up to $85 million upon the achievement of certain development and product profile milestones, including long-acting release formulations. These milestones were convertible into Amylin equity at Lilly's option. Lilly was also to make additional future payments to Amylin of up to $130 million contingent upon global commercialization of exenatide. US development and commercialization costs were to be shared equally, while development costs outside the US were to be shared 80% by Lilly and 20% by Amylin. Lilly was to be responsible for all commercialization costs outside the US. The companies were to share US copromotion, while Lilly was to be the exclusive marketer in all other countries. Operating profits from US sales were to be shared equally. Outside the US, operating profits were to be shared 80% to Lilly and 20% to Amylin [&lt;ulink linkType="reference" linkID="464704"&gt;464704&lt;/ulink&gt;].   &lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2003-12-18T00:00:00Z</Date><Drugs><DrugLink id="13572" nameDisplay="exenatide"/></Drugs><PaymentsToPrincipal><Payment><Reference id="517558">517558</Reference><Type>Other Milestones</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2003 Q3" exchangeRateUS="1">35</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;In December 2003, Eli Lilly gave Amylin a $35 million milestone payment for completing phase III trials. Lilly relinquished rights to convert the milestone payment into Amylin common stock [&lt;ulink linkType="reference" linkID="517558"&gt;517558&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Development Milestone</Type></Event><Event><Date>2004-07-26T00:00:00Z</Date><Drugs><DrugLink id="13572" nameDisplay="exenatide"/></Drugs><PaymentsToPrincipal><Payment><Reference id="550794">550794</Reference><Type>Other Milestones</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2004 Q2" exchangeRateUS="1">5</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;In July 2004, Eli Lilly made a $5 million milestone payment to Amylin after positive results from a trial in type II diabetes patients [&lt;ulink linkType="Reference" linkID="550794"&gt;550794&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Development Milestone</Type></Event><Event><Date>2007-07-23T00:00:00Z</Date><Drugs><DrugLink id="13572" nameDisplay="exenatide"/></Drugs><PaymentsToPrincipal><Payment><Reference id="815100">815100</Reference><Type>Other Milestones</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2007 Q2" exchangeRateUS="1">15</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;By July 2007, Amylin had received a $15 million milestone from Eli Lilly for the launch of the drug in Europe in the second quarter of 2007 [&lt;ulink linkType="Reference" linkID="815100"&gt;815100&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Commercial Milestone</Type></Event><Event><Date>2010-12-31T00:00:00Z</Date><Drugs><DrugLink id="13572" nameDisplay="exenatide"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1166200">1166200</Reference><Type>Other Milestones</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2010 Q3" exchangeRateUS="1">10</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;By December 2010, Amylin had earned a $10 million milestone related to launch of exenatide in Japan [&lt;ulink linkType="Reference" linkID="1166200"&gt;1166200&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Commercial Milestone</Type></Event><Event><Date>2011-11-08T00:00:00Z</Date><Drugs><DrugLink id="13572" nameDisplay="exenatide"/><DrugLink id="15534" nameDisplay="exenatide (controlled-release, Medisorb), AstraZeneca"/><DrugLink id="71833" nameDisplay="exenatide (microsphere suspension formulation, type 2 diabetes), Astrazeneca"/></Drugs><Summary>&lt;para&gt;In November 2011, the companies agreed to end their  collaboration  for exenatide and  controlled-release formulation &lt;ulink linkType="Drug" linkID="15534"&gt;Bydureon&lt;/ulink&gt; in order to resolve the outstanding litigation between them. Lilly would return worldwide rights back to Amylin, beginning in the US on November 30, 2011 and expanding to all markets by the end of 2013. Amylin had filed a US lawsuit against Lilly in May 2011 alleging a breach of the  agreement as a result of Lilly's commercialization agreement with &lt;ulink linkType="Company" linkID="14881"&gt;Boehringer Ingelheim&lt;/ulink&gt; for the competitor product &lt;ulink linkType="Drug" linkID="55852"&gt;Tradjenta&lt;/ulink&gt; (linagliptin). At that time, Amylin sought both a preliminary and permanent injunction against Lilly, with principal action to prevent Lilly from using the same sales force to market both products [&lt;ulink linkType="Reference" linkID="1191897"&gt;1191897&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1192000"&gt;1192000&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1192085"&gt;1192085&lt;/ulink&gt;]. Under the new terms, Amylin would make a one-time, upfront payment to Lilly of $250 million. Amylin would also  make future revenue sharing payments to Lilly equal to 15 % of global net sales of exenatide products until Amylin makes aggregate payments to Lilly of $1.2 billion.  Amylin would also pay Lilly a $150 million milestone on FDA approval of a &lt;ulink linkType="Drug" linkID="71833"&gt;once monthly suspension version of exenatide&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1237315"&gt;1237315&lt;/ulink&gt;]. &lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event><Event><Date>2012-08-09T00:00:00Z</Date><Drugs><DrugLink id="13572" nameDisplay="exenatide"/><DrugLink id="15534" nameDisplay="exenatide (controlled-release, Medisorb), AstraZeneca"/><DrugLink id="71833" nameDisplay="exenatide (microsphere suspension formulation, type 2 diabetes), Astrazeneca"/></Drugs><PaymentsToPartner><Payment><Reference id="1314371">1314371</Reference><Type>Other</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2012 Q2" exchangeRateUS="1">1259</USDAmountMil></Value></Payment></PaymentsToPartner><Summary>&lt;para&gt;In August 2012, following its acquisition by &lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb&lt;/ulink&gt;, Amylin  made a revenue sharing obligation payment valued at $1.259 billion   to Lilly with respect to exenatide  [&lt;ulink linkType="Reference" linkID="1314371"&gt;1314371&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="13572" type="Drug"><TargetEntity id="271636" type="siDrug">Exenatide</TargetEntity></SourceEntity><SourceEntity id="14216" type="Company"><TargetEntity id="4295905544" type="organizationId">Amylin Pharmaceuticals LLC</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"/><TargetEntity id="10067585" type="MEDDRA"/><TargetEntity id="D003924" type="MeSH"/><TargetEntity id="-1888632793" type="omicsDisease"/><TargetEntity id="509" type="siCondition"/></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="136931"><Title>Lundbeck and Otsuka to develop psychiatric and neuroscience drugs aripiprazole, OPC-34712, Lu-AE58054, Lu-AF20513 worldwide and nalmefene in Japan</Title><CompanyPrincipal id="18717">Otsuka Pharmaceutical Co Ltd</CompanyPrincipal><CompanyPartner id="17900">H Lundbeck A/S</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="200.0" min="200.0"/><ValueProjected accuracy="&gt;" max="3600.0" min="3600.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="=" max="221.5176" min="221.5176"/><ValueProjected accuracy="&gt;" max="825.0" min="150.0"/></ValuesToPartner><TerritoriesIncluded><Territory id="WO">World</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPartner><Payment><Reference>1389348</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1507953</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="150.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2013 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1494524</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1494524</Reference><Type>Royalty(%)</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1389348</Reference><Type>Sales Milestones</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1389348</Reference><Type>Other Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="675.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q4">0.0</ReportedAmountMil></Value></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference>1238903</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="200.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2011 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1395810</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1389348</Reference><Type>Profit Split(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2012 Q4">50.0</ReportedAmountMil></Value></Payment><Payment><Reference>1238885</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1200.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2011 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1238885</Reference><Type>Sales Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="400.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2011 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1389348</Reference><Type>Profit Split(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2012 Q4">50.0</ReportedAmountMil></Value></Payment><Payment><Reference>1238903</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="200.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2011 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1395810</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1238885</Reference><Type>Sales Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="400.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2011 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1238885</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1200.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2011 Q3">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="60">Central nervous system disease</Indication><Indication id="11">Alcoholism</Indication><Indication id="14">Alzheimers disease</Indication><Indication id="533">Mood disorder</Indication><Indication id="207">Psychiatric disorder</Indication><Indication id="299">Schizophrenia</Indication></Indications><ActionsPrimary><Action id="7343">Beta amyloid antagonist</Action><Action id="60164">Opioid receptor mu inverse agonist</Action><Action id="585">5-HT 2a receptor antagonist</Action><Action id="22294">Opioid receptor delta inverse agonist</Action><Action id="288">Opioid receptor antagonist</Action><Action id="54302">Opioid receptor kappa partial agonist</Action><Action id="1924">5-HT 6 receptor antagonist</Action><Action id="1920">5-HT 7 receptor modulator</Action><Action id="1846">5-HT 2a receptor modulator</Action><Action id="1210">5-HT 1a receptor modulator</Action><Action id="11845">Dopamine D2 receptor partial agonist</Action><Action id="11842">5-HT 1a receptor partial agonist</Action></ActionsPrimary><ActionsSecondary><Action id="12379">Therapeutic vaccine</Action><Action id="59620">Unspecified drug target</Action><Action id="2943">Antipsychotic</Action><Action id="2941">Antidepressant</Action><Action id="284">Nootropic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="596">Injectable formulation</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="589">Sustained release formulation</Technology><Technology id="595">Tablet formulation</Technology></Technologies><DateStart>2011-11-11T00:00:00Z</DateStart><DateEventMostRecent>2017-02-14T00:00:00Z</DateEventMostRecent><Drugs><Drug id="3673"><DrugNameDisplay>nalmefene</DrugNameDisplay><PhaseHighestStart id="L">Launched</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug><Drug id="89105"><DrugNameDisplay>Lu-AF20513</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="S">Suspended</PhaseHighestNow></Drug><Drug id="106460"><DrugNameDisplay>brexpiprazole (depot formulation, schizophrenia), Otsuka/Lundbeck</DrugNameDisplay><PhaseHighestStart id="C2">Phase 2 Clinical</PhaseHighestStart><PhaseHighestNow id="C1">Phase 1 Clinical</PhaseHighestNow></Drug><Drug id="53257"><DrugNameDisplay>aripiprazole (intramuscular), Otsuka/BMS</DrugNameDisplay><PhaseHighestStart id="L">Launched</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug><Drug id="64328"><DrugNameDisplay>aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</DrugNameDisplay><PhaseHighestStart id="L">Launched</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug><Drug id="7781"><DrugNameDisplay>aripiprazole</DrugNameDisplay><PhaseHighestStart id="L">Launched</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug><Drug id="42300"><DrugNameDisplay>idalopirdine</DrugNameDisplay><PhaseHighestStart id="C3">Phase 3 Clinical</PhaseHighestStart><PhaseHighestNow id="DX">Discontinued</PhaseHighestNow></Drug><Drug id="62001"><DrugNameDisplay>brexpiprazole</DrugNameDisplay><PhaseHighestStart id="C3">Phase 3 Clinical</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In November 2011, &lt;ulink linkType="Company" linkID="17900"&gt;Lundbeck&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="18717"&gt;Otsuka Pharmaceutical&lt;/ulink&gt; entered into a long-term, sales and cost share agreement to develop and commercialize five early and late stage psychiatric and neuroscience candidates, including Otsuka's &lt;ulink linkType="Drug" linkID="64328"&gt;aripiprazole depot formulation&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="62001"&gt;OPC-34712&lt;/ulink&gt; and Lundbeck's three early stage projects to treat psychotic disorders, including schizophrenia, mood and behavioural disorders worldwide [&lt;ulink linkType="Reference" linkID="1238885"&gt;1238885&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1238903"&gt;1238903&lt;/ulink&gt;]. In March 2013, the companies agreed to expand the collaboration to promote all formulations of &lt;ulink linkType="Drug" linkID="7781"&gt;Abilify&lt;/ulink&gt;, including swallowable tablet, oral solution, orally-disintegrating tablet and the &lt;ulink linkType="Drug" linkID="53257"&gt;IM rapid injectable&lt;/ulink&gt; in 14 European countries  [&lt;ulink linkType="Reference" linkID="1389348"&gt;1389348&lt;/ulink&gt;]. In March 2013, the companies expanded the alliance, whereby Otsuka Pharmaceutical signed a license agreement to acquire co-development and co-commercialization rights of Lundbeck's &lt;ulink linkType="Drug" linkID="42300"&gt;Lu-AE58054&lt;/ulink&gt; for the treatment of Alzheimer's disease [&lt;ulink linkType="Reference" linkID="1395810"&gt;1395810&lt;/ulink&gt;]. In October 2013, Lundbeck received an upfront payment   following the expansion of the partnership to include the development and commercialization of   &lt;ulink linkType="Drug" linkID="3673"&gt;nalmefene&lt;/ulink&gt; for alcohol dependence in Japan  [&lt;ulink linkType="Reference" linkID="1494548"&gt;1494548&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1494524"&gt;1494524&lt;/ulink&gt;]. In December 2013, the companies further  expanded the collaboration to include the development of &lt;ulink linkType="Drug" linkID="89105"&gt;Lu-AF20513&lt;/ulink&gt; for Alzheimer's disease [&lt;ulink linkType="Reference" linkID="1507953"&gt;1507953&lt;/ulink&gt;]. By February 2017, Otsuka and Lundbeck were developing a &lt;ulink linkType="Drug" linkID="106460"&gt;long-acting injectable formulation&lt;/ulink&gt; of brexpiprazole for the potential treatment of schizophrenia, thus presumed to be part of the deal [&lt;ulink linkType="Reference" linkID="1929288"&gt;1929288&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1927182"&gt;1927182&lt;/ulink&gt;]. &lt;/para&gt;</Summary><TimeLine><Event><Date>2017-02-14T00:00:00Z</Date><Drugs><DrugLink id="106460" nameDisplay="brexpiprazole (depot formulation, schizophrenia), Otsuka/Lundbeck"/></Drugs><Summary>&lt;para&gt;- By February 2017, Otsuka and Lundbeck were developing a &lt;ulink linkType="Drug" linkID="106460"&gt;long-acting injectable formulation&lt;/ulink&gt; of brexpiprazole for the potential treatment of schizophrenia, thus presumed to be part of the deal [&lt;ulink linkType="Reference" linkID="1929288"&gt;1929288&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1927182"&gt;1927182&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2011-11-11T00:00:00Z</Date><Drugs><DrugLink id="62001" nameDisplay="brexpiprazole"/><DrugLink id="64328" nameDisplay="aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1238903">1238903</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2011 Q3" exchangeRateUS="1">200</USDAmountMil></Value></Payment></PaymentsToPrincipal><StageNotes>&lt;para&gt;Aripiprazole depot NDA to be submitted soon; OPC-34712 has completed Phase III testing&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;In November 2011, &lt;ulink linkType="Company" linkID="17900"&gt;Lundbeck&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="18717"&gt;Otsuka Pharmaceutical&lt;/ulink&gt; entered into a long-term, sales and cost share agreement to develop and commercialize five early and late stage psychiatric and neuroscience candidates, including Otsuka's &lt;ulink linkType="Drug" linkID="64328"&gt;aripiprazole depot formulation&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="62001"&gt;OPC-34712&lt;/ulink&gt; and Lundbeck's three early stage projects to treat psychotic disorders, including schizophrenia, mood and behavioural disorders worldwide [&lt;ulink linkType="Reference" linkID="1238885"&gt;1238885&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1238903"&gt;1238903&lt;/ulink&gt;]. Lundbeck would receive 50% of European  (EU5 and the 4 Nordic countries) and Canada net sales for aripiprazole depot formulation and OPC-34712. Lundbeck would also receive 45% of US net sales for OPC-34712 and 20% for aripiprazole from Otsuka.    The development and commercialization costs would be shared in the same ratio. Otsuka would have  the rights in many of the Asian countries including Japan, as well as Turkey and Egypt. Lundbeck would market the compound and Otsuka would supply the bulk product at a price of agreed percentage of the sales. Otsuka would be responsible for development costs of OPC-34712 up to certain amount and would also equally share the costs afterwards.  Under the terms of the agreement, Otsuka would have an option to codevelop and comarket up to three early stage compounds in Lundbeck's R&amp;amp;D pipeline in certain geographical regions. Lundbeck and Otsuka were discussing for those three compounds to be included in the collaboration. The parties would share costs and sales efforts according to territory splits in cocommercialization countries.  Otsuka would book all sales in the US, Canada, EU5 and the 4 Nordic countries. Lundbeck would book all sales and would be responsible for commercialization in the rest of Europe and the world, excluding many of the Asian countries, as well as Turkey and Egypt. Otsuka would retain the codevelopment and comarketing rights when a sales organization was established   in Lundbeck's territory.  Lundbeck was granted codevelopment and comarketing rights to aripiprazole depot formulation and OPC-34712 in the Europe, Australia, North and Latin America,  and some other countries.  Lundbeck would make an upfront payment upon signing of $200 million and would totally pay up to approximately  $1.8 billion to Otsuka, including upfront payment, development, regulatory and sales milestone payments. Both the companies would share the development,  commercialization and sales   costs based on the agreement [&lt;ulink linkType="Reference" linkID="1238885"&gt;1238885&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1238903"&gt;1238903&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2013-03-06T00:00:00Z</Date><Drugs><DrugLink id="53257" nameDisplay="aripiprazole (intramuscular), Otsuka/BMS"/><DrugLink id="62001" nameDisplay="brexpiprazole"/><DrugLink id="64328" nameDisplay="aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck"/><DrugLink id="7781" nameDisplay="aripiprazole"/></Drugs><Summary>&lt;para&gt;- In March 2013, the companies agreed to expand the collaboration to promote all formulations of &lt;ulink linkType="Drug" linkID="7781"&gt;Abilify&lt;/ulink&gt;, including swallowable tablet, oral solution, orally-disintegrating tablet and the &lt;ulink linkType="Drug" linkID="53257"&gt;IM rapid injectable&lt;/ulink&gt; in 14 European countries. &lt;/para&gt;&lt;para&gt;- Under the agreement, Otsuka and Lundbeck would  jointly promote the drug  in Denmark, Finland, Germany, Italy, Spain, Sweden and the United Kingdom, whereby  Lundbeck would  promote Abilify in Austria, Belgium, Ireland, Netherlands, Poland, Portugal and Romania. &lt;/para&gt;&lt;para&gt;- The agreement would be effective from April 1, 2013. &lt;/para&gt;&lt;para&gt;- Financial terms were not disclosed [&lt;ulink linkType="Reference" linkID="1389348"&gt;1389348&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2013-03-26T00:00:00Z</Date><Drugs><DrugLink id="42300" nameDisplay="idalopirdine"/></Drugs><PaymentsToPartner><Payment><Reference id="1395810">1395810</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2012 Q4" exchangeRateUS="1">150</USDAmountMil></Value></Payment></PaymentsToPartner><Summary>&lt;para&gt;- In March 2013, the companies expanded the alliance, whereby Otsuka Pharmaceutical signed a license agreement to acquire co-development and co-commercialization rights of Lundbeck's &lt;ulink linkType="Drug" linkID="42300"&gt;Lu-AE58054&lt;/ulink&gt; for the treatment of Alzheimer's disease. Lundbeck would receive  an initial payment of $150 million (approximately DKK 855 million) upon signing.&lt;/para&gt;&lt;para&gt;-  The companies would share the sales, development and commercialization costs upon the agreement.&lt;/para&gt;&lt;para&gt;-  Lundbeck was also entitled to up to $675 million (approximately DKK 3.9 billion) in regulatory and sales milestones [&lt;ulink linkType="Reference" linkID="1395810"&gt;1395810&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2013-10-31T00:00:00Z</Date><Drugs><DrugLink id="3673" nameDisplay="nalmefene"/></Drugs><PaymentsToPartner><Payment><Reference id="1494524">1494524</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><ReportedAmountMil currency="EUR">50</ReportedAmountMil><USDAmountMil exchangeRatePeriod="2013 Q3" exchangeRateUS="1.3244">66.22</USDAmountMil></Value></Payment></PaymentsToPartner><Summary>&lt;para&gt;- In October 2013, Lundbeck received an upfront payment of EUR 50 million (approximately $66.22 million) following the expansion of the partnership to include the development and commercialization of   &lt;ulink linkType="Drug" linkID="3673"&gt;nalmefene&lt;/ulink&gt; for alcohol dependence in Japan.    &lt;/para&gt;&lt;para&gt;- The parties would jointly finalize the clinical program for nalmefene in Japan. Lundbeck would finance the development costs and produce the tablets for Japan , while having  an option to copromote the drug there. Lundbeck  was entitled to  royalties and sales milestones, with the total value of this agreement to be worth approximately EUR 100 million (approximately $132.44 million) plus royalties. &lt;/para&gt;&lt;para&gt;- Further specific financial terms were undisclosed [&lt;ulink linkType="Reference" linkID="1494548"&gt;1494548&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1494524"&gt;1494524&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2013-12-11T00:00:00Z</Date><Drugs><DrugLink id="89105" nameDisplay="Lu-AF20513"/></Drugs><PaymentsToPartner><Payment><Reference id="1507953">1507953</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><ReportedAmountMil currency="EUR">4</ReportedAmountMil><USDAmountMil exchangeRatePeriod="2013 Q3" exchangeRateUS="1.3244">5.2976</USDAmountMil></Value></Payment></PaymentsToPartner><Summary>&lt;para&gt;- In December 2013, the companies further  expanded the collaboration to include the development of &lt;ulink linkType="Drug" linkID="89105"&gt;Lu-AF20513&lt;/ulink&gt; for Alzheimer's disease. &lt;/para&gt;&lt;para&gt;- The agreement would cover the development of the drug through clinical phase I. &lt;/para&gt;&lt;para&gt;- Following completion of the  phase I study, the parties would have an option to enter into a co-commercialization and co-development agreement. Otsuka would pay  an initial payment of EUR 4 million (approximately  $5.30 million) upon signing, while Lundbeck would finance the phase I development costs. &lt;/para&gt;&lt;para&gt;- Further financial terms were undisclosed [&lt;ulink linkType="Reference" linkID="1507953"&gt;1507953&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event></TimeLine><IsOptional>Y</IsOptional><CrossReferences><SourceEntity id="3673" type="Drug"><TargetEntity id="119082" type="siDrug">Nalmefene</TargetEntity></SourceEntity><SourceEntity id="89105" type="Drug"><TargetEntity id="826315" type="siDrug">Lu-AF-20513</TargetEntity></SourceEntity><SourceEntity id="53257" type="Drug"><TargetEntity id="162295" type="siDrug">Aripiprazole</TargetEntity></SourceEntity><SourceEntity id="7781" type="Drug"><TargetEntity id="162295" type="siDrug">Aripiprazole</TargetEntity></SourceEntity><SourceEntity id="42300" type="Drug"><TargetEntity id="327608" type="siDrug">LY-483518</TargetEntity><TargetEntity id="352895" type="siDrug">Idalopirdine</TargetEntity></SourceEntity><SourceEntity id="62001" type="Drug"><TargetEntity id="676533" type="siDrug">Brexpiprazole</TargetEntity></SourceEntity><SourceEntity id="17900" type="Company"><TargetEntity id="4295866154" type="organizationId">H Lundbeck A/S</TargetEntity></SourceEntity><SourceEntity id="18717" type="Company"><TargetEntity id="5000020419" type="organizationId">Otsuka Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="11" type="ciIndication"><TargetEntity id="F10.2" type="ICD10"/><TargetEntity id="10001639" type="MEDDRA"/><TargetEntity id="D000437" type="MeSH"/><TargetEntity id="-1679518733" type="omicsDisease"/><TargetEntity id="1119" type="siCondition"/></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"/><TargetEntity id="331.0" type="ICD9"/><TargetEntity id="10012271" type="MEDDRA"/><TargetEntity id="D000544" type="MeSH"/><TargetEntity id="-1268969445" type="omicsDisease"/><TargetEntity id="101" type="siCondition"/></SourceEntity><SourceEntity id="207" type="ciIndication"><TargetEntity id="10061284" type="MEDDRA"/><TargetEntity id="D001523" type="MeSH"/><TargetEntity id="-1461364818" type="omicsDisease"/><TargetEntity id="29" type="siCondition"/></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"/><TargetEntity id="10039626" type="MEDDRA"/><TargetEntity id="D012559" type="MeSH"/><TargetEntity id="-729613619" type="omicsDisease"/><TargetEntity id="65" type="siCondition"/></SourceEntity><SourceEntity id="533" type="ciIndication"><TargetEntity id="F34" type="ICD10"/><TargetEntity id="10001443" type="MEDDRA"/><TargetEntity id="D019964" type="MeSH"/><TargetEntity id="-901921432" type="omicsDisease"/><TargetEntity id="45" type="siCondition"/></SourceEntity><SourceEntity id="60" type="ciIndication"><TargetEntity id="D002493" type="MeSH"/></SourceEntity><SourceEntity id="11845" type="Action"><TargetEntity id="1685" type="Mechanism">Dopamine D2 Receptor Partial Agonists</TargetEntity></SourceEntity><SourceEntity id="7343" type="Action"><TargetEntity id="2200" type="Mechanism">Anti-A beta Peptide</TargetEntity><TargetEntity id="966" type="Mechanism">beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors</TargetEntity></SourceEntity><SourceEntity id="54302" type="Action"><TargetEntity id="2268" type="Mechanism">kappa-Opioid Partial Agonists</TargetEntity></SourceEntity><SourceEntity id="288" type="Action"><TargetEntity id="266" type="Mechanism">Opioid Receptor Antagonists</TargetEntity><TargetEntity id="2415" type="Mechanism">epsilon-Opioid Receptor Antagonists</TargetEntity><TargetEntity id="2599" type="Mechanism">Opioid Receptor Inverse Agonists</TargetEntity></SourceEntity><SourceEntity id="11842" type="Action"><TargetEntity id="905" type="Mechanism">5-HT1A Receptor Partial Agonists</TargetEntity></SourceEntity><SourceEntity id="585" type="Action"><TargetEntity id="210" type="Mechanism">5-HT2A Antagonists</TargetEntity></SourceEntity><SourceEntity id="1210" type="Action"><TargetEntity id="1131" type="Mechanism">5-HT1A Receptor Ligands</TargetEntity></SourceEntity><SourceEntity id="1920" type="Action"><TargetEntity id="1967" type="Mechanism">5-HT7 Receptor Ligands</TargetEntity></SourceEntity><SourceEntity id="22294" type="Action"><TargetEntity id="2087" type="Mechanism">delta-Opioid Inverse Agonists</TargetEntity></SourceEntity><SourceEntity id="1846" type="Action"><TargetEntity id="1966" type="Mechanism">5-HT2A Receptor Ligands</TargetEntity></SourceEntity><SourceEntity id="1924" type="Action"><TargetEntity id="217" type="Mechanism">5-HT6 Antagonists</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="142022"><Title>AstraZeneca to develop Ardelyx' NHE3 inhibitor program, including RDX-5791 for hypernatremia and hyperphosphatemia worldwide      </Title><CompanyPrincipal id="1055312">Ardelyx Inc</CompanyPrincipal><CompanyPartner id="14190">AstraZeneca plc</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="105.5" min="105.5"/><ValueProjected accuracy="&gt;" max="1764.5" min="1764.5"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="=" max="15.0" min="15.0"/><ValueProjected accuracy="&gt;" max="41.0" min="41.0"/></ValuesToPartner><TerritoriesIncluded><Territory id="WO">World</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPartner><Payment><Reference>1666490</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2012 Q3">10.0</ReportedAmountMil></Value></Payment><Payment><Reference>1666490</Reference><Type>Other</Type><Value accuracy="&gt;="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="20.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1666490</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>2144569</Reference><Type>Other</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="6.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1666490</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="15.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1666490</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1666490</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="2012 Q3">10.0</ReportedAmountMil></Value></Payment></PaymentsToPartner><PaymentsToPrincipal><Payment><Reference>1329183</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1329183</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1329183</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="35.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1586515</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="24.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="35.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1646155</Reference><Type>Sales Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="597.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="237.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Sales Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="597.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q3">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="237.5" usdExchangeRate="1.0" usdExchangeRatePeriod="2012 Q3">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="112">Endocrine disease</Indication><Indication id="2740">Hypernatremia</Indication><Indication id="1003">Hyperphosphatemia</Indication></Indications><ActionsPrimary><Action id="13779">Sodium hydrogen exchanger 3 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1332">Gastrointestinal system agent</Action><Action id="2659">Cardioprotectant</Action><Action id="2657">Antihypertensive</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><DateStart>2012-10-08T00:00:00Z</DateStart><DateEnd>2015-06-02T00:00:00Z</DateEnd><DateEventMostRecent>2015-11-02T00:00:00Z</DateEventMostRecent><Drugs><Drug id="71247"><DrugNameDisplay>tenapanor</DrugNameDisplay><PhaseHighestStart id="C3">Phase 3 Clinical</PhaseHighestStart><PhaseHighestNow id="PR">Pre-registration</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In October 2012, &lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca&lt;/ulink&gt; signed an exclusive global agreement to develop &lt;ulink linkType="Company" linkID="1055312"&gt;Ardelyx&lt;/ulink&gt;' NHE3 inhibitor program, including &lt;ulink linkType="Drug" linkID="71247"&gt;RDX-5791&lt;/ulink&gt;, to treat complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD), including hypernatremia  [&lt;ulink linkType="Reference" linkID="1329183"&gt;1329183&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1586515"&gt;1586515&lt;/ulink&gt;]. In January 2014, Ardelyx received a development milestone payment   [&lt;ulink linkType="Reference" linkID="1515358"&gt;1515358&lt;/ulink&gt;]. By March 2014, Ardelyx had received reimbursements for development efforts [&lt;ulink linkType="Reference" linkID="1586515"&gt;1586515&lt;/ulink&gt;]. In May 2014, Ardelyx received a development milestone payment,  as a result of first patient dosing in a phase IIb  trial [&lt;ulink linkType="Reference" linkID="1557310"&gt;1557310&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1586515"&gt;1586515&lt;/ulink&gt;]. In June 2015, Ardelyx terminated the license agreement with  AstraZeneca by regaining the rights to  tenapanor and related portfolio of NHE3 compounds [&lt;ulink linkType="Reference" linkID="1666156"&gt;1666156&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1666490"&gt;1666490&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2144567"&gt;2144567&lt;/ulink&gt;].In November 2015, the termination agreement was amended [&lt;ulink linkType="Reference" linkID="2144569"&gt;2144569&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;/para&gt;</Summary><TimeLine><Event><Date>2015-11-02T00:00:00Z</Date><Drugs><DrugLink id="71247" nameDisplay="tenapanor"/></Drugs><PaymentsToPrincipal><Payment><Reference id="2144569">2144569</Reference><Type>Other</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2015 Q3" exchangeRateUS="1">6</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;- In November 2015, the termination agreement was amended.&lt;/para&gt;&lt;para&gt;- In consideration of the delivery of the CTM,  AstraZeneca would receive a transfer price of $8,000,000.&lt;/para&gt;&lt;para&gt;-  Ardelyx would pay   AstraZeneca $6,000,000 within 15 days after the amendment.&lt;/para&gt;&lt;para&gt;-  Ardelyx would pay  $2,000,000 after the release and delivery of all of the CTM to the MSA and Ardelyx would pay such invoice within 30 days  if the CTM described  would be  released to Ardelyx under quarantine.&lt;/para&gt;&lt;para&gt;- AstraZeneca might not invoice Ardelyx $2,000,000 unless and until such CTM is released from quarantine [&lt;ulink linkType="Reference" linkID="2144569"&gt;2144569&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2012-10-08T00:00:00Z</Date><Drugs><DrugLink id="71247" nameDisplay="tenapanor"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1329183">1329183</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2012 Q3" exchangeRateUS="1">35</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="C2">Phase 2 Clinical</Stage><StageNotes>&lt;para&gt;Ardelyx has completed a Phase II trial of RDX5791 in IBS-C patients&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In October 2012, &lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca&lt;/ulink&gt; signed an exclusive global agreement to develop &lt;ulink linkType="Company" linkID="1055312"&gt;Ardelyx&lt;/ulink&gt;' NHE3 inhibitor program, including &lt;ulink linkType="Drug" linkID="71247"&gt;RDX-5791&lt;/ulink&gt;, to treat complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD), including hypernatremia.&lt;/para&gt;&lt;para&gt;- RDX5791 is an inhibitor of NHE3, a sodium transporter on the surface of the intestinal epithelia.&lt;/para&gt;&lt;para&gt;- Ardelyx has completed a Phase II trial of RDX5791 in IBS-C patients (ClinicalTrials.gov Identifier: NCT01340053).&lt;/para&gt;&lt;para&gt;- AstraZeneca would provide $35 million  upfront, development milestones of $237.5 million, and milestone payments for launch and commercialization.&lt;/para&gt;&lt;para&gt;- AstraZeneca would also provide tiered, double-digit royalties. Ardelyx would conduct phase II  trials, while AstraZeneca bear the development costs.&lt;/para&gt;&lt;para&gt;- Ardelyx had secured an option to copromote the product in the US under agreed limitations.&lt;/para&gt;&lt;para&gt;- It was later disclosed that Ardelyx was eligible for up to $597.5 million for achieving any sales and launch milestones.&lt;/para&gt;&lt;para&gt;- In addition, Ardelyx had an option to  fund the first phase III development program for the first indication for the first licensed product by paying either $20 million, $30 million or $40 million, corresponding to a 1%, 2% or 3% increase in net royalties, respectively.&lt;/para&gt;&lt;para&gt;- The option was exercisable within 60 days following AstraZeneca's decision to begin the first phase III program for tenapanor for a specific indication [&lt;ulink linkType="Reference" linkID="1586515"&gt;1586515&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1329183"&gt;1329183&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2014-01-13T00:00:00Z</Date><Drugs><DrugLink id="71247" nameDisplay="tenapanor"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1515358">1515358</Reference><Type>Other Milestones</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2013 Q4" exchangeRateUS="1">15</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;In January 2014, Ardelyx received a development milestone payment of $15 million from AstraZeneca as part of the collaboration agreement [&lt;ulink linkType="Reference" linkID="1515358"&gt;1515358&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Development Milestone</Type></Event><Event><Date>2014-05-15T00:00:00Z</Date><Drugs><DrugLink id="71247" nameDisplay="tenapanor"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1557310">1557310</Reference><Type>Other Milestones</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2014 Q1" exchangeRateUS="1">25</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;In May 2014, Ardelyx received a development milestone payment of $25 million as a result of first patient dosing in a phase IIb  trial. Under the collaboration, Ardelyx received a total of $75 million in upfront and milestone payments from AstraZeneca [&lt;ulink linkType="Reference" linkID="1557310"&gt;1557310&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1586515"&gt;1586515&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Development Milestone</Type></Event><Event><Date>2014-03-31T00:00:00Z</Date><Drugs><DrugLink id="71247" nameDisplay="tenapanor"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1586515">1586515</Reference><Type>Other</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2013 Q4" exchangeRateUS="1">24.5</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;By March 2014, Ardelyx had been reimbursed $24.5 million for development efforts [&lt;ulink linkType="Reference" linkID="1586515"&gt;1586515&lt;/ulink&gt;]. &lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2015-06-02T00:00:00Z</Date><Drugs><DrugLink id="71247" nameDisplay="tenapanor"/></Drugs><PaymentsToPartner><Payment><Reference id="1666490">1666490</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2015 Q1" exchangeRateUS="1">15</USDAmountMil></Value></Payment></PaymentsToPartner><Stage id="C3">Phase 3 Clinical</Stage><StageNotes>&lt;para&gt;tenapanor is in phase III clinical development&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;- In June 2015, Ardelyx terminated the license agreement with  AstraZeneca by regaining the rights to  tenapanor and related portfolio of NHE3 compounds.&lt;/para&gt;&lt;para&gt;- Pursuant to the termination Agreement, all licenses granted by the Ardelyx were terminated, except for the limited purpose of allowing AstraZeneca to satisfy its obligations.&lt;/para&gt;&lt;para&gt;- AstraZeneca would  assign certain agreements and licenses and would  provide  licenses, data, records and other materials to facilitate the  continued development and commercialization.&lt;/para&gt;&lt;para&gt;- AstraZeneca would  also supply  clinical trial material and certain other materials, drug substances and drug products using transfer pricing for the aggregate amount of up to $10 million.&lt;/para&gt;&lt;para&gt;- AstraZeneca would receive an upfront fee of $15 million, future royalties at a royalty rate of 10% of net sales, 20% of non-royalty revenue received from a new collaboration, or  provide rights to a third party to develop and commercialize the drug with all such amounts not to exceed $90 million.&lt;/para&gt;&lt;para&gt;- AstraZeneca would also receive $10 million as reimbursement for research and development expenses [&lt;ulink linkType="Reference" linkID="1666156"&gt;1666156&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1666490"&gt;1666490&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2144567"&gt;2144567&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;b&gt;Termination Reason : &lt;/b&gt; Unknown/Unspecified &lt;/para&gt;&lt;para&gt;&lt;b&gt;Product Reversion Rights : &lt;/b&gt; to Licensor – payments unknown &lt;br/&gt;- Ardelyx terminated the agreement with AstraZeneca and regained worldwide development and commercialization rights to its portfolio of NHE3 inhibitors, including tenapanor. &lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event></TimeLine><IsOptional>Y</IsOptional><CrossReferences><SourceEntity id="71247" type="Drug"><TargetEntity id="730303" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="1055312" type="Company"><TargetEntity id="5000885818" type="organizationId">Ardelyx Inc</TargetEntity></SourceEntity><SourceEntity id="1003" type="ciIndication"><TargetEntity id="10020711" type="MEDDRA"/><TargetEntity id="D054559" type="MeSH"/><TargetEntity id="-503652923" type="omicsDisease"/><TargetEntity id="1000" type="siCondition"/></SourceEntity><SourceEntity id="112" type="ciIndication"><TargetEntity id="10014698" type="MEDDRA"/><TargetEntity id="D004700" type="MeSH"/><TargetEntity id="-202336293" type="omicsDisease"/><TargetEntity id="501" type="siCondition"/></SourceEntity><SourceEntity id="2740" type="ciIndication"><TargetEntity id="10020679" type="MEDDRA"/><TargetEntity id="D006955" type="MeSH"/><TargetEntity id="-1935641600" type="omicsDisease"/><TargetEntity id="3218" type="siCondition"/></SourceEntity><SourceEntity id="13779" type="Action"><TargetEntity id="2273" type="Mechanism">Na+/H+ Exchanger type 3 (NHE-3) Inhibitors</TargetEntity></SourceEntity></CrossReferences></Deal></dealRecordsOutput>